Efficacy and safety of prescription omega-3-acid ethyl esters for the prevention of recurrent symptomatic atrial fibrillation: A prospective study

Craig M. Pratt, James A. Reiffel, Kenneth A. Ellenbogen, Gerald V. Naccarelli, Peter R. Kowey

Research output: Contribution to journalArticle

30 Citations (Scopus)

Abstract

Background: Atrial fibrillation (AF) continues to be one of the most common cardiac problems, placing an expanding burden on the public health system. In several circumstances, AF can increase the risk of stroke and heart failure. Current pharmacologic treatment options are associated with the potential for significant adverse events, which often outweigh the benefits of achieving sinus rhythm. There is evidence to suggest antiarrhythmic benefits of omega-3 polyunsaturated fatty acids; however, the data are not conclusive. This study is designed to further assess the effect of prescription omega-3 ethyl esters (P-OM3) in the prevention of recurrent AF in patients with AF without (significant) structural heart disease. Methods: This trial is a 6-month randomized, double-blind, placebo-controlled, parallel-study design. Patients with confirmed symptomatic paroxysmal or persistent AF (5:1 ratio) will be randomized to receive either 4 g/d P-OM3 (Lovaza; GlaxoSmithKline, Research Triangle Park, NC) or placebo. The primary end point is the first recurrence of symptomatic AF among patients with paroxysmal AF. Secondary end points include the first recurrence of symptomatic AF among all patients. Safety will be assessed regularly. Conclusion: This is the first randomized blinded trial to assess the antiarrhythmic effects of 4 g/d P-OM3 in paroxysmal AF.

Original languageEnglish (US)
Pages (from-to)163-169.e3
JournalAmerican Heart Journal
Volume158
Issue number2
DOIs
StatePublished - Aug 2009

Fingerprint

Atrial Fibrillation
Prescriptions
Esters
Prospective Studies
Safety
Acids
Placebos
Recurrence
Omega-3 Fatty Acids
Unsaturated Fatty Acids
Heart Diseases
Heart Failure
Public Health
Stroke
Research

All Science Journal Classification (ASJC) codes

  • Cardiology and Cardiovascular Medicine

Cite this

@article{cc6cc4ca17854970bd9735989e592685,
title = "Efficacy and safety of prescription omega-3-acid ethyl esters for the prevention of recurrent symptomatic atrial fibrillation: A prospective study",
abstract = "Background: Atrial fibrillation (AF) continues to be one of the most common cardiac problems, placing an expanding burden on the public health system. In several circumstances, AF can increase the risk of stroke and heart failure. Current pharmacologic treatment options are associated with the potential for significant adverse events, which often outweigh the benefits of achieving sinus rhythm. There is evidence to suggest antiarrhythmic benefits of omega-3 polyunsaturated fatty acids; however, the data are not conclusive. This study is designed to further assess the effect of prescription omega-3 ethyl esters (P-OM3) in the prevention of recurrent AF in patients with AF without (significant) structural heart disease. Methods: This trial is a 6-month randomized, double-blind, placebo-controlled, parallel-study design. Patients with confirmed symptomatic paroxysmal or persistent AF (5:1 ratio) will be randomized to receive either 4 g/d P-OM3 (Lovaza; GlaxoSmithKline, Research Triangle Park, NC) or placebo. The primary end point is the first recurrence of symptomatic AF among patients with paroxysmal AF. Secondary end points include the first recurrence of symptomatic AF among all patients. Safety will be assessed regularly. Conclusion: This is the first randomized blinded trial to assess the antiarrhythmic effects of 4 g/d P-OM3 in paroxysmal AF.",
author = "Pratt, {Craig M.} and Reiffel, {James A.} and Ellenbogen, {Kenneth A.} and Naccarelli, {Gerald V.} and Kowey, {Peter R.}",
year = "2009",
month = "8",
doi = "10.1016/j.ahj.2009.05.024",
language = "English (US)",
volume = "158",
pages = "163--169.e3",
journal = "American Heart Journal",
issn = "0002-8703",
publisher = "Mosby Inc.",
number = "2",

}

Efficacy and safety of prescription omega-3-acid ethyl esters for the prevention of recurrent symptomatic atrial fibrillation : A prospective study. / Pratt, Craig M.; Reiffel, James A.; Ellenbogen, Kenneth A.; Naccarelli, Gerald V.; Kowey, Peter R.

In: American Heart Journal, Vol. 158, No. 2, 08.2009, p. 163-169.e3.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Efficacy and safety of prescription omega-3-acid ethyl esters for the prevention of recurrent symptomatic atrial fibrillation

T2 - A prospective study

AU - Pratt, Craig M.

AU - Reiffel, James A.

AU - Ellenbogen, Kenneth A.

AU - Naccarelli, Gerald V.

AU - Kowey, Peter R.

PY - 2009/8

Y1 - 2009/8

N2 - Background: Atrial fibrillation (AF) continues to be one of the most common cardiac problems, placing an expanding burden on the public health system. In several circumstances, AF can increase the risk of stroke and heart failure. Current pharmacologic treatment options are associated with the potential for significant adverse events, which often outweigh the benefits of achieving sinus rhythm. There is evidence to suggest antiarrhythmic benefits of omega-3 polyunsaturated fatty acids; however, the data are not conclusive. This study is designed to further assess the effect of prescription omega-3 ethyl esters (P-OM3) in the prevention of recurrent AF in patients with AF without (significant) structural heart disease. Methods: This trial is a 6-month randomized, double-blind, placebo-controlled, parallel-study design. Patients with confirmed symptomatic paroxysmal or persistent AF (5:1 ratio) will be randomized to receive either 4 g/d P-OM3 (Lovaza; GlaxoSmithKline, Research Triangle Park, NC) or placebo. The primary end point is the first recurrence of symptomatic AF among patients with paroxysmal AF. Secondary end points include the first recurrence of symptomatic AF among all patients. Safety will be assessed regularly. Conclusion: This is the first randomized blinded trial to assess the antiarrhythmic effects of 4 g/d P-OM3 in paroxysmal AF.

AB - Background: Atrial fibrillation (AF) continues to be one of the most common cardiac problems, placing an expanding burden on the public health system. In several circumstances, AF can increase the risk of stroke and heart failure. Current pharmacologic treatment options are associated with the potential for significant adverse events, which often outweigh the benefits of achieving sinus rhythm. There is evidence to suggest antiarrhythmic benefits of omega-3 polyunsaturated fatty acids; however, the data are not conclusive. This study is designed to further assess the effect of prescription omega-3 ethyl esters (P-OM3) in the prevention of recurrent AF in patients with AF without (significant) structural heart disease. Methods: This trial is a 6-month randomized, double-blind, placebo-controlled, parallel-study design. Patients with confirmed symptomatic paroxysmal or persistent AF (5:1 ratio) will be randomized to receive either 4 g/d P-OM3 (Lovaza; GlaxoSmithKline, Research Triangle Park, NC) or placebo. The primary end point is the first recurrence of symptomatic AF among patients with paroxysmal AF. Secondary end points include the first recurrence of symptomatic AF among all patients. Safety will be assessed regularly. Conclusion: This is the first randomized blinded trial to assess the antiarrhythmic effects of 4 g/d P-OM3 in paroxysmal AF.

UR - http://www.scopus.com/inward/record.url?scp=67650567090&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=67650567090&partnerID=8YFLogxK

U2 - 10.1016/j.ahj.2009.05.024

DO - 10.1016/j.ahj.2009.05.024

M3 - Article

C2 - 19619690

AN - SCOPUS:67650567090

VL - 158

SP - 163-169.e3

JO - American Heart Journal

JF - American Heart Journal

SN - 0002-8703

IS - 2

ER -